Abiraterone acetate in Molecular Apocrine breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002525-29

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To estimate antitumor activity of abiraterone acetate, as measured by the 6 months clinical benefit rate (CBR) in molecular apocrine HER2-negative locally advanced or metastatic breast cancer.


Critère d'inclusion

  • Molecular apocrine locally advanced or metastatic breast cancer

Liens